PubMed Health⌕ Search

Biomedical subjects

R Richie

Publications and source records attributed to R Richie.

16 recordsLinked to original sources
PubMed1998

Renal function in primary liver transplant recipients receiving neoral (cyclosporine) versus prograf (tacrolimus).

Immunosuppressive efficacy of Neoral and Prograf following primary hepatic transplantation was comparable. Incidence of rejection episodes, infectious complications, hypertension, and postoperative diabetes mellitus was comparable. Although clinical use of both immunosuppressants was associated with early compromise in renal function, no progressive renal dysfunction was observed.

Analysis of Variance↗
PubMed1998

Impact of Sandimmune, Neoral, and Prograf on rejection incidence and renal function in primary liver transplant recipients.

Following primary liver transplantation, immunosuppressive efficacy of Neoral and Prograf was similar and superior to that of Sandimmune. Rejection incidence was statistically increased with Sandimmune therapy. Incidence of hypertension, posttransplant diabetes mellitus, and infectious complications was not statistically different. Although early compromise in renal function was associated with Sandimmune, Neoral, and Prograf immunosuppression, no progressive renal dysfunction was identified.

Adult↗
PubMed1994

Fragile X phenotype in a patient with a large de novo deletion in Xq27-q28.

A 2-year-old boy with manifestations of the fragile X syndrome was found to have a cytogenetically visible deletion of Xq27-q28 including deletion of FMR-1. Molecular analysis of the patient was recently described in Tarleton et al. [1993: Hum Mol Genet 2(11): 1973-1974] and the deletion was estimated to be at least 3 megabases (Mb). His mother had 2 FMR-1 alleles with normal numbers of CGG repeats, 20 and 32, respectively. Thus, the deletion occurred as a de novo event. The patient does not appear to have clinical or laboratory findings other than those typically associated with fragile X syndrome, suggesting that the deletion does not remove other contiguous genes. This report describes the phenotype of the patient, including psychological studies.

Chromosome Fragility↗
PubMed1987

Central venous dialysis access: experience with a dual-lumen, silicone rubber catheter.

The central venous dialysis catheter has gained wide acceptance for short-term hemodialysis with the realization of the need to spare peripheral extremity vessels for the creation of more durable internal arteriovenous fistulas. The Hemocath (Quinton Instrument Co., Seattle, Wash.), a soft, silicone rubber, double-lumen central venous dialysis catheter, was introduced as a permanent access device in 1984. A prospective evaluation of 53 catheters placed in 51 patients over a 9-month period is presented. Forty-nine catheters were placed for temporary access and four were placed for permanent access. All 53 catheters were discontinued after functioning an average of 63.9 days (range, 5 to 324 days). No major complications occurred during insertion or on dialysis. One catheter fragmented during removal and was retrieved in the operating room. Infection led to the removal of 17 catheters (34.7%). Thrombosis occurred in 11 catheters and was the cause of removal in two (4.1%). Excluding the two catheters that functioned at the time of the patient's deaths and those placed for permanent access, 91.5% of the catheters performed successfully as temporary accesses devices until permanent access sites were available for use. The catheter provided reliable, relatively safe, and easily maintained central venous access for hemodialysis.

Adult↗